a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced that the company will be presenting its latest research results at both the Association for Research in Vision and Ophthalmology annual meeting, and at two meetings sponsored by the Ophthalmology Innovation Source (OIS) in early May.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
